Larsucosterol (sodium)

• Description:

  Larsucosterol (DUR-928) sodium, a cholesterol metabolite, is a potent liver X receptor (LXR) antagonist. Larsucosterol sodium as a potent endogenous regulator decreases lipogenesis. Larsucosterol sodium inhibits the cholesterol biosynthesis via decreasing mRNA levels and inhibiting the activation of SREBP-1[1][2][3].

• Product Name Alternative:

  DUR-928 (sodium)

• UNSPSC:

  12352100

• Target:

  Endogenous Metabolite; LXR

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/larsucosterol-sodium.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C[C@@]12[C@] (CC[C@]2 ([H]) [C@H] (C) CCCC (C) (O) C) ([H]) [C@@]3 ([H]) [C@@] (CC1) ([H]) [C@@]4 (C (C[C@H] (CC4) OS (=O) (O[Na]) =O) =CC3) C

• Molecular Formula:

  C27H45NaO5S

• Molecular Weight:

  504.70

• References & Citations:

  [1]Ren S, et, al. Sulfated oxysterol, 25HC3S, is a potent regulator of lipid metabolism in human hepatocytes. Biochem Biophys Res Commun. 2007 Sep 7;360 (4) :802-8.|[2]Ma Y, et, al. 25-Hydroxycholesterol-3-sulfate regulates macrophage lipid metabolism via the LXR/SREBP-1 signaling pathway. Am J Physiol Endocrinol Metab. 2008 Dec;295 (6) :E1369-79.|[3]Xu L, et, al. 5-cholesten-3β,25-diol 3-sulfate decreases lipid accumulation in diet-induced nonalcoholic fatty liver disease mouse model. Mol Pharmacol. 2013 Mar;83 (3) :648-58.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 2

• CAS Number:

  1174047-40-5